Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors
Design and optimization of a novel series of imidazo[1,2-b]pyridazine PDE10a inhibitors are described. Compound 31 displays excellent pharmacokinetic properties and was also evaluated as an insulin secretagogue in vitro and in vivo.
Meegalla, Sanath K.,Huang, Hui,Illig, Carl R.,Parks, Daniel J.,Chen, Jinsheng,Lee, Yu-Kai,Wilson, Kenneth J.,Patel, Sharmila K.,Cheung, Wing S.,Lu, Tianbao,Kirchner, Thomas,Askari, Hossein B.,Geisler, John,Patch, Raymond J.,Gibbs, Alan C.,Rady, Brian,Connelly, Margery,Player, Mark R.
PDE 10a Inhibitors for the Treatment of Type II Diabetes
Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.
-
Paragraph 0727-0730
(2015/01/06)
PDE 10a Inhibitors for the Treatment of Type II Diabetes
Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.
-
Paragraph 0474; 0475
(2015/01/06)
More Articles about upstream products of 98431-45-9